{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:45:39Z","timestamp":1761540339980},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2672,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2001,3,14]]},"abstract":"<jats:p>This study reports the generation of an immunodeficient murine model for haemophilia B, obtained by breeding factor IX\u2010deficient mice with an immunodeficient mouse strain, and use of this mouse model to evaluate the long\u2010term efficacy and safety of a gene therapy strategy for treating haemophilia B. Nude haemophilic mice were implanted with biocompatible microcapsules enclosing recombinant myoblasts secreting human factor IX. The activated partial thromboplastin time (APTT) of plasma of mice thus treated was invariably shortened 3\u2003weeks after microcapsule implantation, and remained shortened for at least 77\u2003days. Shortening of the APTT of the haemophilia mice coincided with the appearance of human factor IX in mice plasmas (up to 600\u2003ng\u2003mL<jats:sup>\u22121<\/jats:sup> on day 77), and normalization of the tail\u2010bleeding time. Thus, the microencapsulated myoblasts reversed the clinical phenotype of haemophilia B. In contrast, plasmas of immunocompetent haemophilic mice similarly implanted with microcapsules only showed a transient shortening of APTT, and coincident transient delivery of human factor IX antigen. Rapid disappearance of human factor IX from plasmas of immunocompetent mice also coincided with production of antibodies to the human transgene. Significantly, 86% of the nude haemophilia mice developed tumours of myoblast origin. Thus, while this study revealed the feasibility of this gene therapy approach to treat severe haemophilia B, it also highlights the importance of using safer cell lines to prevent tumour development.<\/jats:p>","DOI":"10.1046\/j.1365-2516.2001.00492.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:02:40Z","timestamp":1047423760000},"page":"207-214","source":"Crossref","is-referenced-by-count":28,"title":["Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis"],"prefix":"10.1111","volume":"7","author":[{"given":"G.","family":"Hortelano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. A.","family":"Ofosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"HednerU&DavieEW.Introduction to hemostasis and the vitamin K\u2010dependent coagulation factors In: Scriber CR Beaudet AL Sly WS Valle D. eds.The Metabolic Basis of Inherited Disease5th edn. New York: McGraw\u2010Hill Co. 1989: 2107\u201334."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.35795357875.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440601.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1293-397"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.6.2353"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V91.3.784","article-title":"Human factor IX corrects the bleeding diathesis of mice with haemophilia B","volume":"91","author":"Kung SH","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0797-270"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/4751"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.7.3906"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/4743"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.5.1401"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb04552.x"},{"key":"e_1_2_6_14_2","unstructured":"MickelsonCA.Discussion on Gonadal Biodistribution of Gene Transfer Vectors. In:Summary minutes of the Recombinant DNA Advisory Committee (RAC) National Institutes of Health (NIH) Bethesda Maryland USA June 18\u2013191998."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5448.2244"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/15207"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1182\/blood.V87.12.5095.bloodjournal87125095","article-title":"Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of haemophilia B","volume":"87","author":"Hortelano G","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950017969"},{"key":"e_1_2_6_19_2","unstructured":"ChristensenL DionneKE&LysaghtMJ.Biomedical applications of immobilized cells In: Goosen MFA ed.Fundamentals of Animal Cell Encapsulation and ImmobilizationBoca Raton FL: CRC Press. 1993: 7\u201329."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(84)90107-1"},{"key":"e_1_2_6_21_2","first-page":"39","article-title":"Microencapsulated hepatocytes as a bioartificial liver","volume":"32","author":"Sun A","year":"1986","journal-title":"Transactions Am Soc Art Int Organs"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-7799(90)90139-O"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(91)90022-5"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1993.4.4-433"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.6-879"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01233861"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.8.3357"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.10.3962"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.21.11563"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V92.1.168.413k06_168_174","article-title":"Targeted inactivation of the coagulation factor IX gene causes haemophilia B in mice","volume":"92","author":"Kundu RK","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.14.4831"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.22.10892"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00335a049"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","unstructured":"ChangPL.Calcium phosphate\u2010mediated DNA transfection In: Wolff JA. eds.Gene TherapeuticsBoston MA: Birkh\u00e4user Boston. 1994:157\u201369.","DOI":"10.1007\/978-1-4684-6822-9_9"},{"key":"e_1_2_6_35_2","unstructured":"SambrookJ FritschEF&ManiatisT. Molecular cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory Press 1989."},{"key":"e_1_2_6_36_2","unstructured":"AusubelFM BrentR&KingstonREet\u2003al. eds.Current Protocols in Molecular BiologyNew York: John Wiley and Sons 1998."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/bit.260431005"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.7.2567"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1996.7.14-1743"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V90.3.1075","article-title":"Persistent systemic production of human factor IX in mice by skeletal myoblast\u2010mediated gene transfer: feasibility of repeat application to obtain therapeutic levels","volume":"90","author":"Wang JM","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/73464"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2414846"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00492.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00492.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2516.2001.00492.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:18:27Z","timestamp":1697588307000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2516.2001.00492.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3,14]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,3,14]]}},"alternative-id":["10.1046\/j.1365-2516.2001.00492.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2516.2001.00492.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3,14]]}}}